弥漫性结缔组织疾病相关心力衰竭研究进展  

Heart failure associated with diffuse connective tissue disease

作　　者：汪汉 秦莉 罗强 WANG Han;QIN Li;LUO Qiang(Department of Cardiology,Affiliated Hospital,Southwest Jiaotong University,the Third Peoples′s Hospital of Chengdu,Cheng-du 610014,China)

机构地区：[1]西南交通大学附属医院,成都市第三人民医院心内科,成都610014

出　　处：《实用医学杂志》2022年第10期1175-1180,共6页The Journal of Practical Medicine

基　　金：国家自然科学基金(编号:81300243);四川省中医药管理局项目(编号:2020034);四川省科技厅面上项目(编号:19YYJC0580)。

摘　　要：弥漫性结缔组织疾病相关心力衰竭在临床上并不罕见,其患病、发病率均较高,是结缔组织疾病的一个重要的死亡原因。炎症和免疫反应可能是结缔组织疾病相关心力衰竭的潜在发病机制。越来越多的证据表明传统心血管危险因素(如高血压、糖尿病、血脂异常、肥胖等)并不能完全解释弥漫性结缔组织疾病相关心力衰竭的高发风险,疾病自身和治疗药物所致的心肌损伤也发挥重要作用。目前,针对弥漫性结缔组织疾病相关心力衰竭的诊断与治疗尚无统一的标准,因此临床多遵循现有相关指南执行。此外,控制传统心血管病危险因素和治疗原发病也可能有利于改善患者的预后。Heart failure associated with diffuse connective tissue disease is not rare in clinical practice.This disorder has higher prevalence and incidence and is an important cause of death of connective tissue disease.Inflammation and immune response may be the underlying pathogenesis of heart failure associated with diffuse con⁃nective tissue.More and more evidence indicates that traditional cardiovascular risk factors(hypertension,diabetes mellitus,dyslipidemia,obesity,etc.)can not fully explain the high risks of heart failure associated with diffuse connective tissue disease,and the disease itself and myocardial damage induced by therapeutic drugs also play an important role.At present,there has been no unified standard for the diagnosis and treatment of heart failure associ⁃ated with diffuse connective tissue disease,so clinical therapies mostly follows the existing relevant guidelines.In addition,control of traditional cardiovascular risk factors and treatment of primary disease may also help to improve the prognosis in patients.

关 键 词：弥漫性结缔组织疾病 心力衰竭 系统性红斑狼疮 类风湿关节炎 

分 类 号：R541.6[医药卫生—心血管疾病]